Oncological treatment of meningeal carcinomatosis;Meningeal karcinomatose

Ugeskrift for Laeger

Volumn 167, Issue 37, 2005, Pages 3481-3484

  Sulim, Sofia ^a,b   Høyer, Morten ^b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; METHOTREXATE;

ADVANCED CANCER; AWARENESS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; HUMAN; NEUROIMAGING; PALLIATIVE THERAPY; PROGNOSIS; REVIEW; SURVIVAL TIME; MENINGIOMA; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; SURVIVAL RATE;

COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; HUMANS; MENINGEAL NEOPLASMS; PALLIATIVE CARE; PROGNOSIS; SURVIVAL RATE;

EID: 24644488739     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982;49:759-72.
2. De Angelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998;38:245-52.
3. Jason GS, Howell A. Carcinomatous meningitis in solid tumours. Ann Oncol 1996;7:773-86.
4. Demopoulos A. Leptomeningeal metastases. Curr Neurol Neirosci Rep 2004;4:196-204.
5. Arita N, Taneda M, Hayakawa T. Leptomeningeal dissemination of malignant gliomas. Acta Neurochir 1994;126:84-92.
6. Grossmann SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 1999;25:103-19.
7. Grisold W, Drlicek M, Setine U. LC: clinical syndrome in different primaries. J Neurooncol 1998;38:103-10.
8. Kerr JZ, Berg S, Blaney SM. Intrathecal chemotherapy. Crit Rev Oncol Hematol 2001;37:227-36.
9. Weitzner MA, Olofsson SM, Forman AD. Patients with malignant meningitis presenting with neuropsychiatric manifestations. Cancer 1995;76:1804-8.
10. Straathof CSM, de Bruin HG, Dippel DWJ et al. The diagnostic accuracy of magnetic resonance imaging and cerebral fluid cytology in leptomeningeal metastasis. J Neurol 1999;246:810-4.
11. Freilich RJ, Krol G, de Angelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38:51-7.
12. Glantz MJ, Cole BF, Glantz LK et al. Cerebrospinal fluid cytology in patients with cancer. Minimizing false-negative results. Cancer 1998;82:733-9.
13. Kaplan J, DeSouza T, Farkash A et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990;92:25-9.
14. Rhodes CH, Glantz MJ, Glantz L et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 1996;77:543-8.
15. Scrideli CA, Øueroz RP, Takayanagui OM et al. Polymerase chain reaction on cerebrospinal fluid cells in suspected leptomeningeal involvement in childhood acute lymphoblastic leukaemia: comparison to cytomorphological analysis. Diagn Mol Pathol 2003;12:124-7.
16. Collie DA, Brush JP, Lammie GA et al. Imaging features of leptomeningeal metastases. Clin Radiol 1999;54:765-71.
17. Chamberlain M, Sandy A, Press G. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990;40:435-8.
18. Tetef ML, Margolin KA, Doroshow JH et al. Pharmacokinetics and toxicity of high-dose methotraxate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 2000;46:19-26.
19. Wellwood J, Taylor K. Central nervous system prophylaxis in haematological malignancies. Intern Med J 2002;32:252-8.
20. Chamberlain MC, Kormanik PRN. Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 1997;35:55-64.
21. Nakagawa H, Murasawa A, Kubo S et al. Diagnosis and treatment of patients with meningeal carcinomatosis. J Neurooncol 1992;13:81-9.
22. Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of inta-CSF-chemotherapy? J Neurooncol 1998;38:151-7.
23. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series with and without intracerebrospinal fluid chemotherapy. Cancer 1998;82:1756-63.
24. Orlando L, Curigliano G, Colleoni M et al. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Anticancer Res 2002;22:3057-60.
25. Fizazi K, Asselain B, Vincent-Salomon A et al. Meningeal carcinomatosis in patients with, and results of high-dose intrathecal methotrexat regimen. Cancer 1996;77:1315-23.
26. Chamberlain M. Neoplastic meningitis: a guide to diagnosis and treatment. Curr Opin Neurol 2000;13:641-8.
27. Grossmann SA, Finkelstein DM, Ruckdeshel JC et al. Randomized prospective comparison of intraventricular methotrexat and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 1993;11:561-9.
28. Glantz MJ, Jaeckle KA, Chamberlain M et al. A randomized controlled trial comparing intrathecal sustained-release Cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clinl Cancer Res 1999;5:3394-402.
29. Glantz MJ, LaFolette S, Jaeckle KA et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999;17:3110-6.
30. Blaney SM, Poplack DG. New cytotoxic drugs for intrathecal administration. J Neurooncol 1998;38:219-23.
31. Coakham HB, Kemshead JT. Treatment of neoplastic meningitis by targeted radiation using 131-radiolabelled monoclonal antibodies. J Neuroonkol 1998;38:225-32.